Viking Therapeutics (VKTX) Non-Current Deffered Revenue (2015 - 2018)

Viking Therapeutics has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $12000.0 for Q4 2018.

• Non-Current Deffered Revenue for Q4 2018 came in at $12000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $12000.0 (changed N/A YoY), and the FY2018 annual result was $12000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue came in at $12000.0 for Q4 2018 at Viking Therapeutics, up from $6054.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $31239.0 in Q4 2015 to a low of $6054.0 in Q2 2017.
• The 4-year median for Non-Current Deffered Revenue is $19149.0 (2015), against an average of $18706.3.
• Across the five-year window, Non-Current Deffered Revenue advanced 6.93% in 2016 and plunged 75.44% in 2017, its largest moves.
• Viking Therapeutics' Non-Current Deffered Revenue stood at $31239.0 in 2015, then tumbled by 47.8% to $16307.0 in 2016, then sank by 62.87% to $6054.0 in 2017, then soared by 98.22% to $12000.0 in 2018.
• The last three Non-Current Deffered Revenue figures came in at $12000.0 (Q4 2018), $6054.0 (Q2 2017), and $10862.0 (Q1 2017), per Business Quant data.